The answer: less pain in a defined group
STEP 9 found greater improvement in knee osteoarthritis pain with weekly injectable semaglutide than with placebo. The study enrolled 407 people with obesity, radiographic knee osteoarthritis and moderate-to-severe pain. At 68 weeks, WOMAC pain scores fell by 41.7 points in the semaglutide group and 27.5 points in the placebo group. Both groups received lifestyle counseling.[1]
The 14.2-point difference is the comparison that matters. Quoting only the larger reduction would give the medication credit for improvement also observed with placebo and the shared trial program. A pain score records how symptoms affect the participant; it does not measure the amount of cartilage remaining in a joint.
Read the units before reading the headline
| Measurement | Semaglutide | Placebo | Meaning |
|---|---|---|---|
| WOMAC pain change | −41.7 points | −27.5 points | A symptom score; lower means less pain |
| Body-weight change | −13.7% | −3.2% | Percentage of starting body weight |
Points and percentages should not be combined. A 41.7-point reduction is not a 41.7% reduction in knee damage. Likewise, losing a percentage of starting weight does not specify how far someone can walk, whether stairs become easier, or whether they will need joint surgery. Each of those questions requires its own measurement.
The trial also favored semaglutide on a physical-function measure. That makes the result more useful than a weight-only headline for someone whose main concern is mobility. Nevertheless, an improvement in reported function and a structural change inside a joint remain separate propositions.
Why this is more than a before-and-after story
Knee symptoms can change over time, and people often seek treatment when symptoms are particularly troublesome. Comparing a person only with their own worst week can exaggerate apparent improvement. Random allocation creates a contemporaneous comparison group, helping separate the treatment-associated difference from shared changes in attention, counseling and time.
- PopulationObesity plus symptomatic knee osteoarthritis
- InterventionA specified semaglutide regimen and shared lifestyle support
- OutcomePain and function, not proof of cartilage repair
The design supports a causal interpretation for the tested treatment strategy within the studied population. It does not tell us how much benefit came from reduced mechanical loading versus another biological pathway. To separate those mechanisms, researchers would need a design that can distinguish weight-mediated effects from other effects rather than simply observing both improvements together.
Where the result fits clinically
This evidence concerns knee osteoarthritis in people with obesity. It should not be stretched into a claim that semaglutide repairs any painful joint, treats an acute injury, or substitutes for an evaluation of unexplained pain. A successful study also does not itself create a new labeled indication; current prescribing information defines the approved uses.[2]
For a person already discussing obesity treatment and limited mobility, pain and function can be useful goals to record alongside weight. Practical examples include tolerating a usual walk or managing a flight of stairs. Tracking the same activity over time gives a more interpretable account than an undefined promise to “feel better.” New, rapidly changing or unexplained symptoms still need their own assessment.
Connect the evidence to the kind of care you need
A mobility problem may call for coordination with existing primary or musculoskeletal care. Our PlushCare review examines a broader appointment-based route; the insurance-support shortlist separates coverage work from prescribing. Use the study-reader checklist to record the population and pain outcome, then compare this with FLOW’s kidney endpoints. Those trials answer different questions about the same ingredient.